Company intelligence / Profile preview

Cognito Medical

Cambridge, MA, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

In Phase 2 OVERTURE trial, Cognito’s device demonstrated significant slowing of Alzheimer’s progression: - 69% reduction in brain volume loss and a 77% reduction in functional decline compared to control. - No serious treatment-limiting adverse events reported. - Therapy received FDA Breakthrough Device Designation. Pivotal Phase 3 HOPE trial ongoing as of mid–2025.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceNon-pharmacological therapy (non-invasive neuromodulation via auditory and visual stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

CogTx-001

Phase 2

Indications: Alzheimer's disease

Partnerships

No major pharma partnerships publicly disclosed.Potential collaborations with academic institutions including MIT due to founder connections.

Beyond the preview

Go deeper on Cognito Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognito Medical.

Explore the full profile